RMDNYSESurgical & Medical Instruments & ApparatusFiscal year ends June 30Also trades as RSMDF

RESMED INC

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 13, 2026

$239.77+0.80 (+0.33%)

Close on Oct 19, 2026

Market cap: $34.79B
P/E (TTM): 23.0
Dividend yield: 1.00%

RESMED INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30	FY 2018 2018-06-30	FY 2017 2017-06-30	FY 2016 2016-06-30	FY 2015 2015-06-30	FY 2014 2014-06-30	FY 2013 2013-06-30	FY 2012 2012-06-30	FY 2011 2011-06-30	FY 2010 2010-06-30	FY 2009 2009-06-30
Revenue	5,653	5,146	4,685	4,223	3,578	3,197	2,957	2,607	2,340	2,067	1,839	1,679	1,555	1,514	1,369	1,243	1,092	921
Cost of Revenue	2,202	2,091	2,030	1,867	1,554	1,358	1,239	1,113	1,005	865	772	668	565	574	548	502	437	367
Gross Profit	3,452	3,055	2,655	2,356	2,024	1,839	1,718	1,494	1,335	1,202	1,066	1,011	990	941	821	741	655	554
Research & Development	378	331	308	288	254	225	202	181	155	144	119	115	118	120	110	92	75	63
Selling, General & Admin	1,120	993	917	874	738	670	677	645	600	554	488	479	450	431	403	372	329	290
Operating Expenses	1,565	1,370	1,335	1,224	1,024	935	908	915	793	776	638	602	585	586	526	474	415	363
Operating Income	1,887	1,685	1,320	1,132	1,000	904	810	579	542	426	429	409	405	355	294	267	240	190
Interest Expense	–	–	–	–	–	24	40	36	28	28	11	5.78	6.13	6.39	4.79	1.76	2.67	–
Interest & Investment Income	–	–	–	–	–	0.36	1.02	2.30	16	17	17	26	31	39	34	28	17	10
Income from Equity Investments	6.96	3.64	-1.85	-7.27	-8.49	-11	-25	-16	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	33	-7.80	-55	-30	-40	-20	-77	-60	-21	-7.06	11	27	26	30	38	37	20	11
Merger & Restructuring Charges	22	0	64	9.18	0	8.67	0	9.40	18	12	6.91	–	6.33	–	–	–	–	–
Asset Impairment Charges	–	–	–	–	–	0	0	0	0	0	2.82	0	0	0	0	2.26	0	0
Gain (Loss) on Investments	4.35	0	0	9.92	-12	15	-15	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	–	0.71	–	–	–	–	–	–
Legal Settlements	–	–	–	–	0	0	0.60	-41	–	-8.50	–	–	–	-10	–	–	–	–
Pretax Income	1,919	1,678	1,265	1,102	960	884	733	519	521	419	440	436	431	385	332	304	261	202
Income Tax Expense	396	277	244	204	181	409	111	114	206	76	87	83	86	78	77	77	71	55
Net Income	1,523	1,401	1,021	898	779	475	622	405	316	342	352	353	345	307	255	227	190	146
EPS (Basic)(per share)	10.47	9.55	6.94	6.12	5.34	3.27	4.31	2.83	2.21	2.42	2.51	2.51	2.44	2.15	1.75	1.49	1.26	0.97
EPS (Diluted)(per share)	10.43	9.51	6.92	6.09	5.30	3.24	4.27	2.80	2.19	2.40	2.49	2.47	2.39	2.10	1.71	1.44	1.23	0.95
Shares Outstanding (Basic, Weighted)(shares)	146	147	147	147	146	145	144	143	143	141	140	140	141	143	146	152	151	151
Shares Outstanding (Diluted, Weighted)(shares)	146	147	148	147	147	146	146	144	144	142	142	143	144	146	149	157	155	154
Dividend per Share(per share)	2.40	2.12	1.92	1.76	1.68	1.56	1.56	1.48	1.40	1.32	1.20	1.12	1.00	0.68	–	–	–	–
EBITDA	2,088	1,884	1,497	1,297	1,160	1,060	965	730	662	538	516	482	479	433	380	338	302	244
Net Interest Income	–	–	–	-47	-22	-24	-39	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 61.1%
Operating margin: 33.4%
Net margin: 26.9%
Return on equity, FY2026: 24.3%

Financial strength

Current ratio: 3.10
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 105.3%

Valuation

P/E ratio: 23.0
Price to sales: 6.15
Price to book: 5.28
Dividend yield: 1.00%